Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 26;29(22):4564–4574. doi: 10.1158/1078-0432.CCR-22-3915

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. Duration of response among responders with advanced or recurrent EC treated with dostarlimab monotherapy. Patients with (A) dMMR/MSI-H EC (Cohort A1) and (B) MMRp/MSS EC (Cohort A2). Time since initial response and first and subsequent responses are shown. — Duration of response among responders with advanced or recurrent EC treated with dostarlimab monotherapy. Patients with (A) dMMR/MSI-H EC (Cohort A1) and (B) MMRp/MSS EC (Cohort A2). Time since initial response and first and subsequent responses are shown.